PHILADELPHIA, Jan. 6, 2017 /PRNewswire/ -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company, announced today that they will be presenting at the 9th Annual Biotech Showcase Conference being held from January 9th-11th in San Francisco, CA. The company is harnessing the power of the immune system to target a specific protein, MAGE A, in an effort to treat triple negative breast cancer (TNBC).
Date: Wednesday, January 11th, 2017
Time: 2:30PM PST
Location: Room 8, Hilton San Francisco Union Square
ImMAGE President and Chief Operating Officer Mahesh Narayanan will present detailed results of recent animal trials, which confirmed the successful creation of specific immune cells to kill the targeted cancer cells. The company is in the process of raising another round of funding and plans to file for the FDA's IND program for approval into Phase 1 human trials in mid-2018.
Narayanan will be available for discussions which can be scheduled by emailing firstname.lastname@example.org or calling 856-343-2804.
About ImMAGE Biotherapeutics
ImMAGE Biotherapeutics Corp. (OTCMKTS: IMMG) was founded in 2015 to harness the power of the human immune system to treat cancer. The company, which has a presence in the Washington, DC and Philadelphia regions, is developing multiple viable candidates to treat triple-negative breast cancer (TNBC) and has progressed from in-vitro trials to animal testing. The immunotherapy market is expected to grow to $9 billion by 2022 and may be used in up to 60% of cases of advanced cancer. Learn more at www.immagebio.com.
Contact: Jullieanne Cueto
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immage-biotherapeutics-to-present-at-the-9th-annual-biotech-showcase-conference-300386905.html
SOURCE ImMAGE Biotherapeutics Corp.